Clinical Trial: Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea: A Phase 2 Clinical Trial

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06952517) titled 'Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea: A Phase 2 Clinical Trial' on April 23.

Brief Summary: To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.

Study Start Date: March 14

Study Type: INTERVENTIONAL

Condition: Papular-pustular Rosacea Papulopustular Rosacea (PPR) Papulopustular Rosacea

Intervention: DRUG: Clascoterone Cream 1%

Clascoterone 1% cream

Recruitment Status: RECRUITING

Sponsor: Narrows Institute for Biomedical Research

Disclaimer: Curated by HT Syndication....